AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

171.570

-0.750-0.44%

Volume:1.67M

Turnover:287.13M

Market Cap:82.17B

PE:-22.97

High:173.690

Open:171.500

Low:170.750

Close:172.320

52wk High:219.589

52wk Low:90.000

Shares:478.91M

Float Shares:478.91M

Volume Ratio:1.55

T/O Rate:0.35%

Dividend:4.08

Dividend Rate:2.38%

EPS(TTM):-7.470

EPS(LYR):-7.470

ROE:-15.83%

ROA:7.26%

PB:3.98

PE(LYR):-22.97

Loading ...

Overview Company News Filings

3 Australian Dividend Stocks For Income Focused Investors

Simply Wall St.

ASX Midday Sector Update: Healthcare Stocks Rise, Materials Sector Struggles

MT Newswires Live

Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny

ASX Dividend Stocks To Consider In June 2026

Simply Wall St.

CSL (ASX:CSL) Shares Could Be 31.5% Undervalued Before Full Year Results

Simply Wall St.

Dividend Powerhouses 3%+ Yield Three Stocks Hiding Income Upside

Simply Wall St.

FACTBOX-Global drugmakers invest billions to boost US presence

Why CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts

Simply Wall St.

What did Morningstar subscribers buy and sell during May?

Morning Star AU

Chart of the Week: Is CSL finally turning the ship around?

Morning Star AU

CSL Unit Signs Five-Year Lease Contract with Clever Culture Systems for APAS Independence Instrument

MT Newswires Live

CSL Bulls Say Margin Forecasts Are Overly Optimistic -- Market Talk

A Look At CSL (ASX:CSL) Valuation After Guidance Cut Impairments CEO Change And Share Price Rebound

Simply Wall St.

How Investors Are Reacting To CSL (ASX:CSL) US$5b Vifor Impairment And Guidance Reset

Simply Wall St.

Stock Track | CSL Soars 5.02% Intraday on UK Regulatory Approval for AUJEMFLU Vaccine

UK'S MHRA Grants Marketing Authorisation For AUJEMFLU To Protect Adults Over 50 Against Flu

UK's Mhra: Granted Marketing Authorisation for Adjuvanted Trivalent Influenza Vaccine (Aujemflu) to Protect Adults Aged 50 & Over Against Flu

THOMSON REUTERS

BUZZ-Morningstar maintains fair value for CSL despite underperformance

ASX Midday Sector Update: Information Technology Stocks Jump, Healthcare Sector Falls

MT Newswires Live

BUZZ-Australia's CSL falls on Jefferies downgrade to "hold"

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/CSL.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":171.57,"timestamp":1788156720000,"preClose":172.32,"halted":0,"volume":1673346,"delay":0,"changeRate":-0.004352367688022284,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.4699491624581285,"marketStatus":"Closed","change":-0.75,"latestTime":"08-31 16:12:00 AEST","open":171.5,"high":173.69,"low":170.75,"amount":287126143,"amplitude":0.017061,"askPrice":171.57,"askSize":346,"bidPrice":171,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":-7.4699491624581285,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":172.32,"dividendRate":0.023788,"openAndCloseTimeList":[[1788134400000,1788156000000]],"volumeRatio":1.550228,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":172.32,"auctionPrice":171.57,"auctionVolume":956426,"auctionTime":1788156605869,"referencePrice":171.57,"referenceTime":1788172203092,"auction":3,"marketStatus":"盘后竞价","timestamp":1788156605869}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.469949,"volumeRatio":1.550228,"shares":478911979,"dividePrice":4.077056,"high":173.69,"amplitude":0.017061,"preClose":172.32,"low":170.75,"week52Low":90,"pbRate":"3.98","psRate":"3.73","week52High":219.589,"institutionHeld":0,"latestPrice":171.57,"committee":0.552393,"eps":-7.4699491624581285,"divideRate":0.023763,"volume":1673346,"delay":0,"ttmEps":-7.4699491624581285,"open":171.5,"prevYearClose":170.408,"prevWeekClose":172.32,"prevMonthClose":123.06,"prevQuarterClose":114.74,"fiveDayClose":169.11,"twentyDayClose":124.3,"sixtyDayClose":97.91,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.018567360626050477},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2644055595","title":"3 Australian Dividend Stocks For Income Focused Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2644055595","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644055595?lang=en_us&edition=fundamental","pubTime":"2026-06-19 12:55","pubTimestamp":1781844941,"startTime":"0","endTime":"0","summary":"With central banks rethinking rate paths, inflation still a key concern, and energy prices swinging on geopolitical headlines, many investors are looking for income streams that feel steadier than short term market moves. Dividend Powerhouses with yields above 5% and a history of well covered, growing payouts can offer a way to keep cash flow at the center of a portfolio while policy and growth data keep shifting. This article highlights three stocks from the Dividend Powerhouses (3%+ Yield)...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-australian-dividend-stocks-for-income-focused-investors","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/3-australian-dividend-stocks-for-income-focused-investors","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GDX","IAU","XJO.AU","CBA.AU","CSL.AU","OUNZ","AAAU","CEF","DBC","GBUG","GDXD","XKO.AU","IAUI","GDXU","XME","BEAR.AU","JDST","PICK","DUST","SGDM","JNUG","VIG","GLDM","BEGS","ISBC","GOLY","PHYS","RING","GDXJ","EVN.AU","SGOL","GLL","UGL","BTGD","USG","FGDL","DZZ","GLTR","SHNY","OZR.AU","BAR","DGP","GDXY","GIVE.AU","UYM","IAUM","ZYAU.AU","GOAU","XAO.AU","DULL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644304360","title":"ASX Midday Sector Update: Healthcare Stocks Rise, Materials Sector Struggles","url":"https://stock-news.laohu8.com/highlight/detail?id=2644304360","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644304360?lang=en_us&edition=fundamental","pubTime":"2026-06-19 10:45","pubTimestamp":1781837133,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose 1% at midday Friday.CSL  gained nearly 3% in recent trade.On the flip side, the materials sector struggled, shedding 3%.BHP Group  shares were down nearly 4% in recent trade after increasing the estimated investment for its Jansen stage two potash project to $6.9 billion from $4.9 billion following a cost and schedule review.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128526141.USD","XBI","BK4581","HCSG","BHP.AU","BK4588","UYM","LABU","BK4137","BK7508","BK7067","CSL.AU","BK7095","BK4585","BK7501","XLV","BK7511","LU0029874061.USD","BK7507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644140704","title":"Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny","url":"https://stock-news.laohu8.com/highlight/detail?id=2644140704","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644140704?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:00","pubTimestamp":1781776800,"startTime":"0","endTime":"0","summary":"Moderna's mRNA flu vaccine faces FDA advisory panel scrutinyBy Christy Santhosh and Mariam Sunny","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nL4N42P0L7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0784385170.HKD","BK7508","LU1481600234.SGD","LU1496350502.SGD","LU2357627491.SGD","LU0889566641.SGD","LU0432979614.USD","LU0757432116.USD","LU0792757196.USD","LU1291159041.SGD","LU0784384876.USD","LU0957799991.USD","LU0823416689.USD","LU0976567544.SGD","LU2089283258.USD","03165","LU0128525929.USD","LU1046234339.USD","IE00BJJMRZ35.SGD","LU1064927863.SGD","LU0963555726.SGD","LU1084165304.USD","BK4568","LU2293690249.USD","AZN.UK","LU1003076772.USD","LU0203345920.USD","LU2108987350.USD","LU1061106388.HKD","LU0784385840.USD","BK4139","SG9999001176.USD","LU2112291526.USD","LU1323610961.USD","IE00B4R5TH58.HKD","LU0553294199.USD","LU0949170772.SGD","LU1104425308.USD","LU2539964713.USD","LU0640478417.SGD","MRNY","LU1923622614.USD","LU1078025761.USD","CSL.AU","LU0823399737.USD","LU1989771016.USD","MRNA","LU1355424745.HKD","IE0034235188.USD","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644795898","title":"ASX Dividend Stocks To Consider In June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2644795898","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644795898?lang=en_us&edition=fundamental","pubTime":"2026-06-17 03:09","pubTimestamp":1781636974,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a cautious atmosphere amid global geopolitical developments and domestic interest rate uncertainties, investors are closely watching how these factors impact local equities. In such an environment, dividend stocks can offer a measure of stability and income potential, making them an attractive consideration for those looking to balance risk with steady returns.","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/asx-dividend-stocks-to-consider-in-june-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/asx-dividend-stocks-to-consider-in-june-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QFN.AU","GIVE.AU","KSL.AU","BK7062","STW.AU","BK7067","E200.AU","VIG","IISV.AU","CSL.AU","VAP.AU","FID.AU","BK7078","OZF.AU","BK7501","GEAR.AU","BK4588","MFF.AU","DACE.AU","BBOZ.AU","XKO.AU","EQT.AU","IIGF.AU","BK7511","BK7135","IOZ.AU","JIN.AU","ZYAU.AU","BK7508","AUB.AU","DDR.AU","SDF.AU","XAO.AU","BK7101","VAS.AU","BK7145","BK7068","QRE.AU","SLF.AU","PPC.AU","IMLC.AU","CBA.AU","OZR.AU","EIGA.AU","XJO.AU","BEAR.AU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644762852","title":"CSL (ASX:CSL) Shares Could Be 31.5% Undervalued Before Full Year Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2644762852","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644762852?lang=en_us&edition=fundamental","pubTime":"2026-06-17 00:23","pubTimestamp":1781627011,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) is back in focus after a sharp share price rebound, with investors weighing the upcoming August 18 full-year results and dividend announcement against recent guidance cuts and asset impairments.\nSee our latest analysis for CSL.\nThe recent rebound has lifted CSL’s 7 day share price return to 6.8% and its 30 day share price return to 8.5%. However, its year to date share price return is still down 38.2% and the 1 year total shareholder return has declined 54.5%. This indicates...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-shares-could-be-315-undervalued-before-full-year","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-shares-could-be-315-undervalued-before-full-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL","BK7511","LU1169590202.USD","LU1169589451.USD","BK7067","BK7501","CSL.AU","BK7508","LU0728928796.USD","SG9999004303.SGD","BK4086","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644764240","title":"Dividend Powerhouses 3%+ Yield Three Stocks Hiding Income Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2644764240","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644764240?lang=en_us&edition=fundamental","pubTime":"2026-06-17 00:22","pubTimestamp":1781626934,"startTime":"0","endTime":"0","summary":"With inflation trends diverging across regions and central banks keeping investors on edge, many are looking for ways to put cash to work without relying solely on share price moves. That is where Dividend Powerhouses with 3%+ yields come in, focusing on companies that are paying more than a 5% dividend yield that is covered, growing and relatively stable. In this article, the spotlight is on income resilience in a world of shifting rates and mixed growth signals, and it will reveal 3 of the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/dividend-powerhouses-3-yield-three-stocks-hiding-income-upsi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/dividend-powerhouses-3-yield-three-stocks-hiding-income-upsi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GDX","IAUM","XME","BEGS","RING","BAR","DULL","DUST","IAUI","UYM","IAU","JDST","GDXD","GLTR","OUNZ","PHYS","CHAT","DBC","GOAU","GDXJ","CBA.AU","BTGD","GLDM","VIG","AGIX","AAAU","GDXU","ARTY","EVN.AU","GLL","AIPO","JNUG","SHNY","XAO.AU","UGL","USG","DGP","SGDM","GDXY","CSL.AU","PICK","CEF","DZZ","FGDL","SGOL","XKO.AU","AI","XJO.AU","GBUG","GOLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643770522","title":"FACTBOX-Global drugmakers invest billions to boost US presence","url":"https://stock-news.laohu8.com/highlight/detail?id=2643770522","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643770522?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:55","pubTimestamp":1781520920,"startTime":"0","endTime":"0","summary":"FACTBOX-Global drugmakers invest billions to boost US presence Recasts paragraph 1, 2; updates headline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nL4N42N0V9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LU0098860793.USD","LU1046234339.USD","IE00BGHQF631.EUR","03165","AMGN","IE00B19Z3B42.SGD","LU0070302665.USD","LU0985481810.HKD","CSL.AU","LU2023250504.SGD","LU2237443549.SGD","LU2242646821.SGD","LU1929549753.HKD","SG9999018865.SGD","LLYX","ELIL","MRK","LU1430594728.SGD","LU1699723380.USD","LU0047473722.EUR","LU0211327993.USD","PFE","IE00BLSP4452.SGD","AZN.UK","IE00BZ1G4Q59.USD","LU0211331839.USD","LU0109391861.USD","LU0976567544.SGD","GILD","IE00BJT1NW94.SGD","BK4592","LU0708994859.HKD","IE00BSNM7G36.USD","ABBV","LLY","LU0661504455.SGD","ELIS","LLYZ","LU0158827948.USD","LU1496350502.SGD","JNJ","SG9999001440.SGD","LU0029864427.USD","LU2237438978.USD","BIIB","LLII","LU1934455194.USD","SG9999003800.SGD","LU0942090050.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643214189","title":"Why CSL (ASX:CSL) Is Up 9.8% After Cutting FY26 Guidance On Impairments And Channel Shifts","url":"https://stock-news.laohu8.com/highlight/detail?id=2643214189","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643214189?lang=en_us&edition=fundamental","pubTime":"2026-06-13 16:26","pubTimestamp":1781339195,"startTime":"0","endTime":"0","summary":"CSL has recently cut its FY26 revenue and profit forecasts following earnings downgrades, writedowns and impairments tied to shifts in US immunoglobulin sales channels and softer China albumin prices, ahead of its full-year results and dividend announcement previously scheduled for 18 August 2026.\nDespite these setbacks, investors appear increasingly focused on CSL’s turnaround prospects and the possibility that future impairments could be more contained than previously feared.\nWe’ll now...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/why-csl-asxcsl-is-up-98-after-cutting-fy26-guidance-on-impai","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4086","BK7511","CSL.AU","BK7067","LU0728928796.USD","AIPO","CSL","BK7501","BK7508","LU1169589451.USD","SGXZ23171101.USD","LU1169590202.USD","SG9999004303.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642731405","title":"What did Morningstar subscribers buy and sell during May?","url":"https://stock-news.laohu8.com/highlight/detail?id=2642731405","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642731405?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"Sharesight is a portfolio tracker that is integrated into Morningstar Investor. Their data shows the top 20 trades by Morningstar subscribers in May. Sharesight’s data above ranks total trading activi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/what-did-morningstar-subscribers-buy-sell-during-may","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/what-did-morningstar-subscribers-buy-sell-during-may","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["CSL.AU","QRE.AU","BK4588","QFN.AU","IISV.AU","XKO.AU","BBOZ.AU","IMLC.AU","VAP.AU","VAS.AU","BK4550","XJO.AU","GEAR.AU","XLV","BK4112","IIGF.AU","MORN","OZR.AU","BK7501","ZYAU.AU","DACE.AU","GIVE.AU","XAO.AU","IOZ.AU","LABU","BK7067","SEMI.AU","BK4598","SLF.AU","XBI","BK4585","BK7508","SHL.AU","BK7511","BK4581","LU1878469433.USD","LU2065731478.USD","BEAR.AU","STW.AU","EIGA.AU","E200.AU","BK7124","FDN","OZF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642405202","title":"Chart of the Week: Is CSL finally turning the ship around?","url":"https://stock-news.laohu8.com/highlight/detail?id=2642405202","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642405202?lang=en_us&edition=fundamental","pubTime":"2026-06-11 00:00","pubTimestamp":1781107200,"startTime":"0","endTime":"0","summary":"The week’s insights come from equity strategist Lochlan Halloway’s latest analysis of CSL Ltd (ASX.CSL).CSL faces headwinds but shares remain cheap ahead of expected margin recoveryCSL is a global lea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"morningstar_stock","url":"https://www.morningstar.com.au/stocks/chart-week-is-csl-finally-turning-ship-around","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/stocks/chart-week-is-csl-finally-turning-ship-around","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["BK4086","BK7067","CSL","BK7511","CSL.AU","LU1169589451.USD","LU0728928796.USD","LU2355687059.USD","LU1064131342.USD","LU2211815571.USD","LU1988902786.USD","LU2264538146.SGD","LU2249611893.SGD","IE00BFMHRM44.USD","GTLS","LU0823414478.USD","BK7508","BK7501","IE00B19Z4B17.USD","IE0031619046.USD","SG9999004303.SGD","SGXZ23171101.USD","LU2048586759.USD","IE00B66KJ199.SGD","LU1169590202.USD","BK4161","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642845800","title":"CSL Unit Signs Five-Year Lease Contract with Clever Culture Systems for APAS Independence Instrument","url":"https://stock-news.laohu8.com/highlight/detail?id=2642845800","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642845800?lang=en_us&edition=fundamental","pubTime":"2026-06-09 09:12","pubTimestamp":1780967525,"startTime":"0","endTime":"0","summary":"CSL's  CSL Behring subsidiary signed a five-year contract with Clever Culture Systems  for the lease of an APAS Independence instrument and environmental monitoring analysis modules, according to a Tuesday filing with the Australian bourse.APAS Independence is an instrument that automates the imaging, interpretation, and reporting of microbial growth on culture plate media for labs.The contract will be paid in monthly installments, with an initial minimum non-cancellable period of six months following the start of the company's formal validation, which must occur on or before Dec. 31, the filing said.CSL shares rose 1% in morning trade on Tuesday, while Clever Culture Systems shares were up 5%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LU0728928796.USD","LU1169590202.USD","BK7511","BK7501","SGXZ23171101.USD","LU1169589451.USD","BK7007","SG9999004303.SGD","BK4086","CSL.AU","BK7508","CSL","CC5.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642745862","title":"CSL Bulls Say Margin Forecasts Are Overly Optimistic -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2642745862","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642745862?lang=en_us&edition=fundamental","pubTime":"2026-06-09 08:43","pubTimestamp":1780965780,"startTime":"0","endTime":"0","summary":"0043 GMT - CSL's bulls at UBS think analysts elsewhere are too optimistic about the scale of margin improvement the Australian biotech can deliver in its next fiscal year. UBS analysts keep a buy rating on the stock but warn clients in a note that the consensus forecast of a 90-basis-point margin expansion at CSL's plasma-product business is too high. They expect to see an improvement on a 10% lift in collections per donor, which they say will help offset price and competitive pressures. However, there will be no return to pre-Covid levels, they add. The UBS analysts are untroubled by the hefty impairments CSL has announced. UBS cuts its target price 9.7% to A$158.00. Shares are up 0.6% at A$98.49. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CSL","UBS","CSL.AU","LU0728928796.USD","BK4086","BK7508","LU1863844665.USD","LU1829250122.USD","SG9999004303.SGD","LU3187612489.SGD","BK4118","BK4585","BK4534","LU1863844749.USD","IE0034235071.USD","LU1169589451.USD","SGXZ23171101.USD","BK4588","LU1169590202.USD","BK7511","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641239101","title":"A Look At CSL (ASX:CSL) Valuation After Guidance Cut Impairments CEO Change And Share Price Rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2641239101","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641239101?lang=en_us&edition=fundamental","pubTime":"2026-06-08 12:34","pubTimestamp":1780893256,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) is back in focus after cutting its FY26 revenue guidance, flagging about US$5b in additional Vifor related impairments and progressing a CEO transition along with broader commercial restructuring.\nSee our latest analysis for CSL.\nCSL’s share price rose 5.75% in the last session to A$97.91 and is up 1.35% over seven days. However, the 30 day share price return is down 18.33% and the one year total shareholder return is down 58.53%, which points to fading longer term momentum...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-look-at-csl-asxcsl-valuation-after-guidance-cut-impairment","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/a-look-at-csl-asxcsl-valuation-after-guidance-cut-impairment","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSL.AU","BK7501","SGXZ23171101.USD","SG9999004303.SGD","CSL","BK7511","LU0728928796.USD","LU1169589451.USD","BK7067","BK7508","LU1169590202.USD","BK4086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641123670","title":"How Investors Are Reacting To CSL (ASX:CSL) US$5b Vifor Impairment And Guidance Reset","url":"https://stock-news.laohu8.com/highlight/detail?id=2641123670","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641123670?lang=en_us&edition=fundamental","pubTime":"2026-06-06 03:22","pubTimestamp":1780687323,"startTime":"0","endTime":"0","summary":"In recent weeks, CSL Limited cut its FY26 revenue and earnings guidance, flagged around US$5.00 billion in additional non-cash impairments largely tied to CSL Vifor, and continued a leadership transition while pursuing a broad operational transformation program.\nThese developments highlight how earlier capital allocation decisions and current restructuring efforts are reshaping CSL’s risk profile, management credibility, and future profitability mix across its core plasma, vaccines, and iron...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-are-reacting-to-csl-asxcsl-us5b-vifor-impairme","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/how-investors-are-reacting-to-csl-asxcsl-us5b-vifor-impairme","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SGXZ23171101.USD","BK4023","BK4551","ISBC","BK4588","BK4211","LU0728928796.USD","BK7508","SG9999004303.SGD","BK4528","BK4587","CHAT","BK7067","AGIX","BK7511","BK4543","ARTY","AIPO","CSL","CSL.AU","AIYY","LU1169590202.USD","LU1169589451.USD","BK7501","AI","BK4585","BK4086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144650764","title":"Stock Track | CSL Soars 5.02% Intraday on UK Regulatory Approval for AUJEMFLU Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1144650764","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144650764?lang=en_us&edition=fundamental","pubTime":"2026-06-05 11:36","pubTimestamp":1780630616,"startTime":"0","endTime":"0","summary":"CSL LIMITED's stock soared 5.02% during intraday trading on Friday, following positive regulatory news from the United Kingdom.The UK's Medicines and Healthcare products Regulatory Agency (MHRA)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2641716931","title":"UK'S MHRA Grants Marketing Authorisation For AUJEMFLU To Protect Adults Over 50 Against Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2641716931","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641716931?lang=en_us&edition=fundamental","pubTime":"2026-06-05 00:26","pubTimestamp":1780590376,"startTime":"0","endTime":"0","summary":"June 4 (Reuters) - UK's MHRA::*UK'S MHRA: GRANTED MARKETING AUTHORISATION FOR ADJUVANTED TRIVALENT INFLUENZA VACCINE (AUJEMFLU) TO PROTECT ADULTS AGED 50  OVER AGAINST FLU*Further company coverage: CS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nRSDRbZ0f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7501","BK7508","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640165171","title":"UK's Mhra: Granted Marketing Authorisation for Adjuvanted Trivalent Influenza Vaccine (Aujemflu) to Protect Adults Aged 50 & Over Against Flu","url":"https://stock-news.laohu8.com/highlight/detail?id=2640165171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640165171?lang=en_us&edition=fundamental","pubTime":"2026-06-04 23:03","pubTimestamp":1780585404,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C02H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7511","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640260959","title":"BUZZ-Morningstar maintains fair value for CSL despite underperformance","url":"https://stock-news.laohu8.com/highlight/detail?id=2640260959","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640260959?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:33","pubTimestamp":1780436006,"startTime":"0","endTime":"0","summary":"BUZZ-Morningstar maintains fair value for CSL despite underperformance** Morningstar keeps A$165 fair value estimate despite headwinds faced by Australia's CSL Ltd CSL.AX ** Earlier this year, the biotechnology giant cut its annual profit citing regulatory headwinds and weak performance including other reasons** The Investment research firm says shares are undervalued, says it is more optimistic on co's stock than the market on plasma demand and margins ** Morningstar sees co's immunoglobulin revenue to grow at a 10-year compound annual growth rate  of 5% on higher volumes from population growth, rising diagnosis rates including others** Also forecasts plasma gross margins to lift to 100 basis points till FY35, cites efficiency initiatives and rationalization of high-cost collection centers** Says market for plasma products has become increasingly competitive and most cost savings will be offset by price competition ** Adds, separation of CSL Seqirus to  help CSL to refocus on the core","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL6N42A17U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MORN","BK7511","BK7501","BK4598","BK7067","BK4112","LU2065731478.USD","BK7508","CSL.AU","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640663987","title":"ASX Midday Sector Update: Information Technology Stocks Jump, Healthcare Sector Falls","url":"https://stock-news.laohu8.com/highlight/detail?id=2640663987","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640663987?lang=en_us&edition=fundamental","pubTime":"2026-06-01 10:53","pubTimestamp":1780282407,"startTime":"0","endTime":"0","summary":"Information technology stocks advanced more than 5% at midday Monday.Xero (ASX:XRO) gained 8% in recent trade.On the flip side, the healthcare sector struggled, shedding nearly 2%.CSL (ASX:CSL) shares fell almost 2% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XRO.AU","XBI","BK7016","BK7501","BK7511","XLV","BK7067","BK4137","LABU","LU0128526141.USD","BK7508","LU0029874061.USD","III","BK4585","BK4588","CSL.AU","BK7503","BK4581","BK4134","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639649752","title":"BUZZ-Australia's CSL falls on Jefferies downgrade to \"hold\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2639649752","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639649752?lang=en_us&edition=fundamental","pubTime":"2026-05-29 13:36","pubTimestamp":1780032982,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL falls on Jefferies downgrade to \"hold\"** Shares of biotechnology major CSL Ltd CSL.AX fall as much as 2.5% to A$95.16, their lowest level since May 12 ** Jefferies downgrades CSL to \"hold\" from \"buy\", citing limited near-term growth in its Vifor division amid rising competitive pressures** Cuts price target to A$108 from A$195 after shifting to peerbased valuation and lowering earnings forecasts** Says CSL Vifor faces pricing pressure from generic iron products and insurer step-edits favouring lower-cost treatments** Adds lower-than-expected CHF/USD forex forecast to impact Vifor revenue and profit** Stock down 43.7% YTD, including the day's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nL4N4260GG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7511","BK7508","CSL.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}